Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK6097608 in Advanced Solid Tumors
NCT04446351Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2020
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of GSK6097608B in solid tumor, sponsored by GSK. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events at 2 years. Started Jun 2020; status: active, not recruiting.
02
Drugs
GSK6097608B
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04446351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446351.